Follow on Google News News By Tag * Pharmaceutical * Healthcare * Ratings * Retail * Drug * Scenario * Sopharma * Generics * Regulatory * Disease * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | New Market Study Published: Bulgaria Pharmaceuticals & Healthcare Report Q4 2010Recently published research from Business Monitor International, "Bulgaria Pharmaceuticals & Healthcare Report Q4 2010", is now available at Fast Market Research
Through to 2014, we expect the market to post a compound annual growth rate (CAGR) of 6.91% in local currency terms (but just of 2.27% in US dollars), reaching BGN2.44bn (US$1.42bn). Inflationary trends - we expect low and steady inflation to persist over the medium term - will contribute to this pattern, as will the fact that volume sales have been falling. Over the 2009-2019 forecast period, growth rates will average 5.47% and 3.16%, respectively. However, foreign direct investment (FDI) will remain conditional on demonstrable progress in tackling corruption in the country. To this end, the Bulgarian Competition Protection Commission (CPC) imposed a BGN30,000 (US$19,299) fine on the National Health Insurance Fund (NZOK) for abusing its monopoly position in July 2010, while a recent investigation into former Bulgarian health minister Bozhidar Nachev has revealed further offences made by the fund's high-profile officers. The share of generics in volume terms has been volatile as older, cheaper medicines have been withdrawn from the market and newer branded generics have been introduced. Nevertheless, the generics market is still calculated to be five times larger than the patented sector by volume. Value-wise, penetration is low compared with many regional markets, despite the country's reference pricing system. In fact, in June 2010, Mila Vlaskovska, Bulgaria's national pharmacology consultant, stated that the value of generic medicines is 30-60% lower than the originator products. By 2014, and despite low prices, we expect the patented market to account for 35% of the total market by value, due to patent expirations and general climate of cost-containment. Nevertheless, the constraints of the domestic market continue to push domestic players to expand abroad. In fact, in June 2010, novinite.com reported that major pharmaceutical companies in Bulgaria registered a 14% year-on-year (y-o-y) increase in combined turnover to BGN154.2mn (US$96.92mn) For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: Executive Summary SWOT Analysis - Bulgaria Pharmaceuticals And Healthcare SWOT - Bulgaria Political SWOT - Bulgaria Economic SWOT - Bulgaria Business Environment SWOT Pharmaceutical Business Environment Ratings - Table: Regional Pharmaceutical Business Environment Ratings Q410 - Rewards - Risks Bulgaria - Market Summary - Regulatory Regime - Recent Regulatory Developments - Intellectual Property Environment - Corruption and Counterfeit Drugs - Pricing Regime - Table: Wholesale Mark-Ups - Table: Retail Mark-Ups - Reimbursement Regime Industry Developments - Epidemiology - Table: Main Causes Of Death In Bulgaria (per 100,000 population - Table: Disease Burden In CEE - Non-Communicable Diseases - Communicable Diseases - Healthcare Sector - Healthcare Financing - National Healthcare Plan - Healthcare Insurance - Hospital Privatisation Programme - Introduction Of Patient E-Cards - Medical Devices - Table: Classification Of Medical Devices In The EU Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Macroeconomic Forecast Scenario - Table: Bulgaria - Economic Activity - Prescription Drug Market Forecast - Patented Drug Market Forecast - Generic Drug Market Forecast - OTC Medicine Market Forecast - Medical Device Market Forecast - Pharmaceutical Trade Forecast - Other Healthcare Data Forecasts - Key Risks To BMI's Forecast Scenario Competitive Landscape - Pharmaceutical Industry - Table: Leading Pharmaceutical Companies By Sales - Local Pharmaceutical Sector - Foreign Pharmaceutical Sector - Wholesale Sector - Table: Pharmaceutical Wholesale and Retail Market in Bulgaria - Retail Sector - Research And Development - Clinical Trials Company Monitor - Indigenous Companies - Sopharma - Biovet - Actavis Bulgaria (formerly Balkanpharma) - Foreign Companies - GlaxoSmithKline - Novartis - Sanofi-Aventis - Pfizer - Merck & Co Country Snapshot: Bulgaria Demographic Data - Section 1: Population - Table: Demographic Indicators, 2005-2030 - Table: Rural/Urban Breakdown, 2005-2030 - Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number